Author - Abby Hardy

Gracell Biotechnologies

Evercore starts Gracell Biotech at OP

Evercore ISI initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with an “outperform” rating and no price target. The stock was quoted at $5.43 midday on Nov. 27. Gracell is developing a unique CAR-T construct...


LENZ Therapeutics, Graphite Bio in merger accord

Closely-held LENZ Therapeutics and Graphite Bio (NASDAQ:GRPH) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company, which will focus on advancing LENZ’...

Annovis Logo

Brookline starts Annovis Bio at buy; PT $35

Brookline Capital Markets initiated coverage of Annovis Bio (NASDAQ:ANVS) with a “buy” rating and price target of $35. The stock was quoted at $5.85 midday on Nov. 10. Annovis is developing treatments for...